Robocath Develop Device To Make Interventional Cardiology Safer

Robocath Develop Device To Make Interventional Cardiology Safer
Coronary heart diseases are among the leading cause of death worldwide. The current gold standard for treatment is an angioplasty, inserting catheters to dilate a blocked coronary artery and reestablish blood circulation. The intervention is minimally invasive and relatively low-risk compared to surgery, and can be carried out on an outpatient basis under local anesthesia.

While the treatment has a high success rate, it also carry some recognized disadvantages. Physicians perform these operations with the use of x-rays and daily exposure can lead to occupational pathologies, making interventional cardiology one of the most irradiated medical professions. In addition, the current protection worn by medical professionals during procedures to guard against radiation is heavy and uncomfortable, and studies have shown that involved hospital staff are more likely to suffer from musculoskeletal problems.

The French startup Robocath is determined to protect physicians from these occupational hazards while ensuring an efficient treatment for patients. They develop an innovative device, called R-one, allowing doctors to perform coronary angioplasties by remotely controlling the catheters whilst seated behind a control station that is protected from x-rays. Using the robot, physicians can carry out a precise, stable, controlled procedure, while improving working conditions, reducing exposure to radiation by up to 95%.

Although advances have been made in interventional cardiology the last decades, there has been little focus on occupational risks. Radiation exposure and the protective attire can lead to career terminating injuries and life-threatening diseases, including cancer. Robocath has developed an innovative system that improve working conditions and safety for health care staff. The technology’s ease of use combined with improved safety could lead to increased access and use of interventional cardiology, offering optimal care for more patients. It could significantly reduce cost of intervention, benefiting patients, doctors and healthcare providers, improving care for one of the leading causes of death worldwide.

R-one is still in approval stages and is currently seeking CE mark. Robocath aims to release the device in Europe and the Middle East in 2018, and anticipates that the market could be worth €4.5 billion. The startup has won multiple awards, including Tech’innov 2015, and in May, 2017 announced they had raised €4.7 million led by M Capital, Normandie Participations, along with Go Capital and NCI.

If you appreciate our work, consider making a contribution